AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01500278 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (ADA)
Description: * Active substance: an injectable volume of 0.8 ml solution for injection ADA~* Pharmaceutical form: prefilled syringes ADA~* Concentration: 40 mg/0.8 ml ADA~* Route of Administration: injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal.
Study NCT01500278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (MTX)
Description: * Active substance: Methotrexate~* Pharmaceutical form: oral tablet~* Concentration: 15-25 mg/week~* Route of Administration: MTX orally
Study NCT03622489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramal
Description: mentioned above
Study NCT04643912 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vibration Device
Description: Device which causes the bone to vibrate and records the spectrum of that vibration
Study NCT03716401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI (magnetic resonance imaging)
Description: An MRI (or magnetic resonance imaging) scan is a radiology technique that uses magnetism, radio waves, and a computer to produce images of body structures. The MRI scanner is a tube surrounded by a circular magnet.
Study NCT03716401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: US (ultrasound)
Description: An ultrasound scan is a medical test that uses high-frequency sound waves to capture live images from the inside of the body.
Study NCT03716401 — intervention group
Intervention type: PROCEDURE
Intervention: Renal Biopsy
Description: A kidney biopsy involves taking one or more tiny pieces (samples) of the kidney to look at with special microscopes. The microscopes make it possible to see the samples in greater detail.
Study NCT03716401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Positron Emission Tomography (PET)
Description: Positron emission tomography (PET) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions. By identifying body changes at the cellular level, PET may detect the early onset of disease before it is evident on other imaging tests.
Study NCT03716401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microvascular Assessment
Description: Glycocalyx (a network of membrane proteoglycans and glycoproteins lining all blood vessels) thickness is non-invasively estimated from video clips of sublingual vessels captured using a hand held microscope. Glycocalyx is vital for vascular health; perturbations in the glycocalyx are thought to contribute to numerous vascular health complications including DKD.
Study NCT02907385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeSeal™ Kit
Description: LifeSeal™ Kit is applied as an additional protective layer over a stapled anastomosis
Study NCT03971201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic resection
Description: removal of portion of liver containing cancer
Study NCT03971201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: sorafenib either as adjuvant therapy after resection or as only treatment
Study NCT03971201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: sorafenib either as adjuvant therapy after resection or as only treatment
Study NCT00053417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 15 weeks
Study NCT00053417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)
Description: 2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)
Study NCT00053417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg fampridine-SR (4-aminopyridine, 4-AP)
Description: 10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)
Study NCT00053417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg fampridine-SR (4-aminopyridine, 4-AP)
Description: 2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)
Study NCT04472585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Injectable Solution
Description: Subcutaneous Ivermectin 200ug/kg body weight 48 hourly
Study NCT04472585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Injectable Placebo
Description: 0.9% normal saline
Study NCT04472585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Zinc Sulphate 20mg 3 times a day
Study NCT04472585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo empty capsule
Description: Placebo empty capsule
Study NCT04472585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo empty capsule
Description: Placebo empty capsule
Study NCT04472585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ivermectin
Description: 0.2mg/kg/day
Study NCT03719274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin c depigementation
Description: locally injected vitamin c depigementation
Study NCT03719274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin c depigementation
Description: locally injected vitamin c depigementation
Study NCT03673774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiac impedancemetry
Description: The cardiac output is measured by impedance measurement at rest and during the walking test.
Study NCT02389803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation standardized formula
Description: Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
Study NCT02389803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Low caloric formula (Powder added to water), without added vitamins and minerals
Study NCT01821651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartNavigator
Description: Procedure with software
Study NCT01821651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchoNav
Description: Procedure with software
Study NCT01821651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control-Group EN
Description: Procedure without software
Study NCT01821651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control-group HN
Description: Procedure without software
Study NCT03901079 — intervention group
Intervention type: OTHER
Intervention: single-arm study
Description: single-arm study
Study NCT03891173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOS47
Description: L-DOS47 lyophilized powder reconstituted and diluted for iv injection
Study NCT03891173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin concentrate for solution for iv infusion
Study NCT03891173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin concentrate for solution for iv infusion
Study NCT03891173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine concentrate for solution for iv infusion
Study NCT03891173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine concentrate for solution for iv infusion
Study NCT00718276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25(OH)D
Description: daily (20ug), weekly (140 ug), Bolus (140 ug)
Study NCT00718276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
Study NCT00855985 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: type of anastomosis after pancreaticoduodenectomy
Description: pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
Study NCT03408392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation A
Description: Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
Study NCT03408392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference formulation B
Description: Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
Study NCT04843007 — intervention group
Intervention type: DRUG
Intervention: Pemetrexed
Description: Alvopem® was administered every 3 weeks with a dose of 500 mg/m\^2
Study NCT01465555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Description: Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
Study NCT02120898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Cream, generic formulation of the brand product.
Study NCT02120898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyclara®
Description: Cream, brand product.
Study NCT02120898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
Study NCT01465919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.
Study NCT01465919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supportive psychotherapy
Description: Supportive psychotherapy will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week in patients with interferon induced depression.
Study NCT02633150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supplementation with red grapes polyphenol
Study NCT02633150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplementation with red grapes polyphenol
Study NCT01477398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QED-100
Description: Use of the QED-100 results in mild hypercapnia during emergence
Study NCT02265770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16 weeks of VEC + CDDP
Description: Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
Study NCT02265770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEC + HD-MTX
Description: Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
Study NCT02265770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Valproate
Description: Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.~Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses.
Study NCT02265770 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy
Description: Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
Study NCT02265770 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conformal radiotherapy
Description: Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
Study NCT02265770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VEC
Description: D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
Study NCT02265770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
Study NCT02265770 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: conformal radiotherapy +/- boost
Description: Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.~In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions
Study NCT02265770 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conformal radiotherapy +/- boost
Description: Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.~In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions
Study NCT03820648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexis
Description: The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.
Study NCT03820648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard 3M™ Steri-Drape 2
Description: Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.
Study NCT02371447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPM1002BC
Description: Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)
Study NCT00634309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Study NCT00634309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03724188 — intervention group
Intervention type: PROCEDURE
Intervention: surgical parathyroidectomy
Description: total parathyroidectomy, subtotal parathyroidectomy, total parathyroidectomy with autotransplantation
Study NCT02424032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and connective tissue massage
Description: Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.
Study NCT02424032 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
Study NCT04558411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy (DBT) Skills
Description: 14 brief videos that teach DBT skills.
Study NCT04283136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Padsevonil type 1 Tablet 200 mg
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period.
Study NCT02808117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: MNP
Description: Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.~One form of micronutrient supplementation proven to effectively combat micronutrient deficiency.
Study NCT00724698 — intervention group
Intervention type: DRUG
Intervention: Desloratadine
Description: Desloratadine 5 mg once daily
Study NCT05871216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical tests and balance evaluation using the Delos Proprioceptive System
Description: Each patient is evaluated using clinical tests (Time up and go test, 6 minutes walking test), scales (BORG scale, Beighton score), and the ''Delos Proprioceptive System'' to assess balance control and proprioception with bipodalic and monopodalic tests.
Study NCT04048356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Description: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Study NCT04048356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Description: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Study NCT04475796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy performed after ERCP
Study NCT01875796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Study NCT01875796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Study NCT01875796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation Enhancement Therapy
Study NCT01875796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivation Enhancement Therapy
Study NCT01875796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Cannabis and Anxiety Reduction Treatment
Study NCT01875796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: False Safety Behavior Elimination Therapy
Study NCT00784914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Receive temsirolimus IV
Study NCT00784914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
Study NCT00784914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cytokine levels
Description: Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
Study NCT00784914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytokine levels
Description: Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors